{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T22:01:36Z","timestamp":1793916096482,"version":"4.8.0"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T00:00:00Z","timestamp":1761696000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T00:00:00Z","timestamp":1761696000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Med Res"],"DOI":"10.1186\/s40001-025-03297-6","type":"journal-article","created":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T13:24:59Z","timestamp":1761744299000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Analysis of common treatment-related adverse events of donafenib and its correlation with efficacy: exploratory analysis of the ZGDH3 study"],"prefix":"10.1186","volume":"30","author":[{"given":"Feng","family":"Bi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shukui","family":"Qin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shanzhi","family":"Gu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuxian","family":"Bai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhendong","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zishu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jieer","family":"Ying","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yinying","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiqiang","family":"Meng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongming","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ping","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xi","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aibing","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chengxu","family":"Cui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bo","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoli","family":"Xin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jufeng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinlu","family":"Shan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junhui","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhendong","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyu","family":"Wen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenyu","family":"You","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenggang","family":"Ren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianming","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chengyou","family":"Du","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingxia","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Longzhen","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Tao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Da","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Senming","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongping","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jifang","family":"Sheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuelong","family":"Zhuang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,29]]},"reference":[{"key":"3297_CR1","doi-asserted-by":"publisher","DOI":"10.1038\/nrdp.2016.18","volume":"2","author":"JM Llovet","year":"2016","unstructured":"Llovet JM, Zucman-Rossi J, Pikarsky E, et al. Hepatocellular carcinoma. Nat Rev Dis Primers. 2016;2:16018. https:\/\/doi.org\/10.1038\/nrdp.2016.18.","journal-title":"Nat Rev Dis Primers"},{"issue":"15","key":"3297_CR2","doi-asserted-by":"publisher","first-page":"1450","DOI":"10.1056\/NEJMra1713263","volume":"380","author":"A Villanueva","year":"2019","unstructured":"Villanueva A. Hepatocellular carcinoma. N Engl J Med. 2019;380(15):1450\u201362. https:\/\/doi.org\/10.1056\/NEJMra1713263.","journal-title":"N Engl J Med"},{"key":"3297_CR3","unstructured":"Globocan 2020 Liver Cancer Fact Sheet. Global cancer observatory. https:\/\/gco.iarc.fr\/today\/data\/factsheets\/cancers\/11-Liver-fact-sheet.pdf. Accessed 10 Mar 2021"},{"key":"3297_CR4","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.00171","author":"P Dasgupta","year":"2020","unstructured":"Dasgupta P, Henshaw C, Youlden DR, Clark PJ, Aitken JF, Baade PD. Global trends in incidence rates of primary adult liver cancers: a systematic review and meta-analysis. Front Oncol. 2020. https:\/\/doi.org\/10.3389\/fonc.2020.00171.","journal-title":"Front Oncol"},{"issue":"2","key":"3297_CR5","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1016\/j.cld.2015.01.001","volume":"19","author":"KA McGlynn","year":"2015","unstructured":"McGlynn KA, Petrick JL, London WT. Global epidemiology of hepatocellular carcinoma: an emphasis on demographic and regional variability. Clin Liver Dis. 2015;19(2):223\u201338. https:\/\/doi.org\/10.1016\/j.cld.2015.01.001.","journal-title":"Clin Liver Dis"},{"key":"3297_CR6","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.ctrv.2018.05.006","volume":"68","author":"J-L Raoul","year":"2018","unstructured":"Raoul J-L, Kudo M, Finn RS, Edeline J, Reig M, Galle PR. Systemic therapy for intermediate and advanced hepatocellular carcinoma: Sorafenib and beyond. Cancer Treat Rev. 2018;68:16\u201324. https:\/\/doi.org\/10.1016\/j.ctrv.2018.05.006.","journal-title":"Cancer Treat Rev"},{"issue":"9822","key":"3297_CR7","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.1016\/S0140-6736(11)61347-0","volume":"379","author":"A Forner","year":"2012","unstructured":"Forner A, Llovet JM, Bruix J. Hepatocellular carcinoma. Lancet Lond Engl. 2012;379(9822):1245\u201355. https:\/\/doi.org\/10.1016\/S0140-6736(11)61347-0.","journal-title":"Lancet Lond Engl"},{"issue":"4","key":"3297_CR8","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1056\/NEJMoa0708857","volume":"359","author":"JM Llovet","year":"2008","unstructured":"Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008;359(4):378\u201390. https:\/\/doi.org\/10.1056\/NEJMoa0708857.","journal-title":"N Engl J Med"},{"issue":"10","key":"3297_CR9","doi-asserted-by":"publisher","first-page":"1452","DOI":"10.1016\/j.ejca.2011.12.006","volume":"48","author":"A-L Cheng","year":"2012","unstructured":"Cheng A-L, Guan Z, Chen Z, et al. Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma according to baseline status: subset analyses of the phase III Sorafenib Asia-Pacific trial. Eur J Cancer. 2012;48(10):1452\u201365. https:\/\/doi.org\/10.1016\/j.ejca.2011.12.006.","journal-title":"Eur J Cancer"},{"issue":"20","key":"3297_CR10","doi-asserted-by":"publisher","first-page":"1894","DOI":"10.1056\/NEJMoa1915745","volume":"382","author":"RS Finn","year":"2020","unstructured":"Finn RS, Qin S, Ikeda M, et al. Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma. N Engl J Med. 2020;382(20):1894\u2013905. https:\/\/doi.org\/10.1056\/NEJMoa1915745.","journal-title":"N Engl J Med"},{"key":"3297_CR11","doi-asserted-by":"publisher","first-page":"133","DOI":"10.2147\/JHC.S224938","volume":"7","author":"AL Raybould","year":"2020","unstructured":"Raybould AL, Sanoff H. Combination antiangiogenic and immunotherapy for advanced hepatocellular carcinoma: Evidence to date. J Hepatocell Carcinoma. 2020;7:133\u201342. https:\/\/doi.org\/10.2147\/JHC.S224938.","journal-title":"J Hepatocell Carcinoma"},{"issue":"3","key":"3297_CR12","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1007\/s00280-020-04031-1","volume":"85","author":"X Li","year":"2020","unstructured":"Li X, Qiu M, Wang S, Zhu H, Feng B, Zheng L. A phase I dose-escalation, pharmacokinetics and food-effect study of oral donafenib in patients with advanced solid tumours. Cancer Chemother Pharmacol. 2020;85(3):593\u2013604. https:\/\/doi.org\/10.1007\/s00280-020-04031-1.","journal-title":"Cancer Chemother Pharmacol"},{"issue":"10","key":"3297_CR13","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.1517\/13543776.2014.943184","volume":"24","author":"GS Timmins","year":"2014","unstructured":"Timmins GS. Deuterated drugs: where are we now? Expert Opin Ther Pat. 2014;24(10):1067\u201375. https:\/\/doi.org\/10.1517\/13543776.2014.943184.","journal-title":"Expert Opin Ther Pat"},{"issue":"15_suppl","key":"3297_CR14","doi-asserted-by":"publisher","first-page":"4506","DOI":"10.1200\/JCO.2020.38.15_suppl.4506","volume":"38","author":"F Bi","year":"2020","unstructured":"Bi F, Qin S, Gu S, et al. Donafenib versus sorafenib as first-line therapy in advanced hepatocellular carcinoma: an open-label, randomized, multicenter phase II\/III trial. J Clin Oncol. 2020;38(15_suppl):4506\u20134506. https:\/\/doi.org\/10.1200\/JCO.2020.38.15_suppl.4506.","journal-title":"J Clin Oncol"},{"issue":"2","key":"3297_CR15","doi-asserted-by":"publisher","DOI":"10.1016\/j.xinn.2020.100032","volume":"1","author":"M Feng","year":"2020","unstructured":"Feng M, Pan Y, Kong R, Shu S. Therapy of primary liver cancer. Innovation (Camb). 2020;1(2):100032. https:\/\/doi.org\/10.1016\/j.xinn.2020.100032.","journal-title":"Innovation (Camb)"},{"issue":"1","key":"3297_CR16","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1634\/theoncologist.2009-0143","volume":"15","author":"B Vincenzi","year":"2010","unstructured":"Vincenzi B, Santini D, Russo A, et al. Early skin toxicity as a predictive factor for tumor control in hepatocellular carcinoma patients treated with sorafenib. Oncologist. 2010;15(1):85\u201392. https:\/\/doi.org\/10.1634\/theoncologist.2009-0143.","journal-title":"Oncologist"},{"issue":"12","key":"3297_CR17","doi-asserted-by":"publisher","first-page":"1233","DOI":"10.1097\/MEG.0b013e32834bd2d0","volume":"23","author":"T Song","year":"2011","unstructured":"Song T, Zhang W, Wu Q, Kong D, Ma W. A single center experience of sorafenib in advanced hepatocellular carcinoma patients: evaluation of prognostic factors. Eur J Gastroenterol Hepatol. 2011;23(12):1233\u20138. https:\/\/doi.org\/10.1097\/MEG.0b013e32834bd2d0.","journal-title":"Eur J Gastroenterol Hepatol"},{"issue":"9","key":"3297_CR18","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1111\/j.1872-034X.2012.00991.x","volume":"42","author":"T Otsuka","year":"2012","unstructured":"Otsuka T, Eguchi Y, Kawazoe S, et al. Skin toxicities and survival in advanced hepatocellular carcinoma patients treated with sorafenib. Hepatol Res. 2012;42(9):879\u201386. https:\/\/doi.org\/10.1111\/j.1872-034X.2012.00991.x.","journal-title":"Hepatol Res"},{"issue":"6","key":"3297_CR19","doi-asserted-by":"publisher","first-page":"950","DOI":"10.1111\/liv.12168","volume":"33","author":"J-Y Cho","year":"2013","unstructured":"Cho J-Y, Paik Y-H, Lim HY, et al. Clinical parameters predictive of outcomes in sorafenib-treated patients with advanced hepatocellular carcinoma. Liver Int. 2013;33(6):950\u20137. https:\/\/doi.org\/10.1111\/liv.12168.","journal-title":"Liver Int"},{"issue":"4","key":"3297_CR20","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1097\/COC.0b013e3182468039","volume":"36","author":"B Estfan","year":"2013","unstructured":"Estfan B, Byrne M, Kim R. Sorafenib in advanced hepatocellular carcinoma: hypertension as a potential surrogate marker for efficacy. Am J Clin Oncol. 2013;36(4):319\u201324. https:\/\/doi.org\/10.1097\/COC.0b013e3182468039.","journal-title":"Am J Clin Oncol"},{"issue":"9","key":"3297_CR21","doi-asserted-by":"publisher","first-page":"670","DOI":"10.4254\/wjh.v6.i9.670","volume":"6","author":"M Shomura","year":"2014","unstructured":"Shomura M, Kagawa T, Shiraishi K, et al. Skin toxicity predicts efficacy to sorafenib in patients with advanced hepatocellular carcinoma. World J Hepatol. 2014;6(9):670\u20136. https:\/\/doi.org\/10.4254\/wjh.v6.i9.670.","journal-title":"World J Hepatol"},{"issue":"35","key":"3297_CR22","doi-asserted-by":"publisher","first-page":"12581","DOI":"10.3748\/wjg.v20.i35.12581","volume":"20","author":"M Yada","year":"2014","unstructured":"Yada M, Masumoto A, Motomura K, et al. Indicators of sorafenib efficacy in patients with advanced hepatocellular carcinoma. World J Gastroenterol. 2014;20(35):12581\u20137. https:\/\/doi.org\/10.3748\/wjg.v20.i35.12581.","journal-title":"World J Gastroenterol"},{"issue":"2","key":"3297_CR23","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1016\/j.jhep.2014.03.030","volume":"61","author":"M Reig","year":"2014","unstructured":"Reig M, Torres F, Rodriguez-Lope C, et al. Early dermatologic adverse events predict better outcome in HCC patients treated with sorafenib. J Hepatol. 2014;61(2):318\u201324. https:\/\/doi.org\/10.1016\/j.jhep.2014.03.030.","journal-title":"J Hepatol"},{"issue":"4","key":"3297_CR24","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1016\/j.jhep.2012.06.014","volume":"57","author":"J Bruix","year":"2012","unstructured":"Bruix J, Raoul J-L, Sherman M, et al. Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: subanalyses of a phase III trial. J Hepatol. 2012;57(4):821\u20139. https:\/\/doi.org\/10.1016\/j.jhep.2012.06.014.","journal-title":"J Hepatol"},{"issue":"10126","key":"3297_CR25","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1016\/S0140-6736(18)30207-1","volume":"391","author":"M Kudo","year":"2018","unstructured":"Kudo M, Finn RS, Qin S, et al. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. Lancet. 2018;391(10126):1163\u201373. https:\/\/doi.org\/10.1016\/S0140-6736(18)30207-1.","journal-title":"Lancet"},{"issue":"3","key":"3297_CR26","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1111\/bcpt.12365","volume":"116","author":"Y Li","year":"2015","unstructured":"Li Y, Gao Z-H, Qu X-J. The adverse effects of sorafenib in patients with advanced cancers. Basic Clin Pharmacol Toxicol. 2015;116(3):216\u201321. https:\/\/doi.org\/10.1111\/bcpt.12365.","journal-title":"Basic Clin Pharmacol Toxicol"},{"issue":"11","key":"3297_CR27","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1691\/ph.2019.9626","volume":"74","author":"J Liu","year":"2019","unstructured":"Liu J, Li X, Zhang H, et al. Safety, pharmacokinetics and efficacy of donafenib in treating advanced hepatocellular carcinoma: Report from a phase 1b trial. Pharm. 2019;74(11):688\u201393. https:\/\/doi.org\/10.1691\/ph.2019.9626.","journal-title":"Pharm"},{"issue":"35","key":"3297_CR28","doi-asserted-by":"publisher","first-page":"12581","DOI":"10.3748\/wjg.v20.i35.12581","volume":"20","author":"M Yada","year":"2014","unstructured":"Yada M. Indicators of sorafenib efficacy in patients with advanced hepatocellular carcinoma. World J Gastroenterol. 2014;20(35):12581. https:\/\/doi.org\/10.3748\/wjg.v20.i35.12581.","journal-title":"World J Gastroenterol"},{"issue":"8","key":"3297_CR29","doi-asserted-by":"publisher","first-page":"1125","DOI":"10.1592\/phco.27.8.1125","volume":"27","author":"CA Grandinetti","year":"2007","unstructured":"Grandinetti CA, Goldspiel BR. Sorafenib and sunitinib: novel targeted therapies for renal cell cancer. Pharmacotherapy. 2007;27(8):1125\u201344. https:\/\/doi.org\/10.1592\/phco.27.8.1125.","journal-title":"Pharmacotherapy"},{"issue":"2","key":"3297_CR30","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1080\/02841860701765675","volume":"47","author":"D Chu","year":"2008","unstructured":"Chu D, Lacouture ME, Fillos T, Wu S. Risk of hand-foot skin reaction with sorafenib: a systematic review and meta-analysis. Acta Oncol. 2008;47(2):176\u201386. https:\/\/doi.org\/10.1080\/02841860701765675.","journal-title":"Acta Oncol"},{"issue":"1","key":"3297_CR31","doi-asserted-by":"publisher","first-page":"11","DOI":"10.3816\/CGC.2009.n.002","volume":"7","author":"D Chu","year":"2009","unstructured":"Chu D, Lacouture ME, Weiner E, Wu S. Risk of hand-foot skin reaction with the multitargeted kinase inhibitor sunitinib in patients with renal cell and non-renal cell carcinoma: a meta-analysis. Clin Genitourin Cancer. 2009;7(1):11\u20139. https:\/\/doi.org\/10.3816\/CGC.2009.n.002.","journal-title":"Clin Genitourin Cancer"},{"key":"3297_CR32","doi-asserted-by":"publisher","first-page":"31","DOI":"10.2147\/JHC.S168953","volume":"6","author":"N Personeni","year":"2019","unstructured":"Personeni N, Pressiani T, Rimassa L. Lenvatinib for the treatment of unresectable hepatocellular carcinoma: Evidence to date. J Hepatocell Carcinoma. 2019;6:31\u20139. https:\/\/doi.org\/10.2147\/JHC.S168953.","journal-title":"J Hepatocell Carcinoma"},{"key":"3297_CR33","unstructured":"Population ages 65 and above (% of total population)-Japan, Italy, Portugal, Germany, Finland | Data. https:\/\/data.worldbank.org\/indicator\/SP.POP.65UP.TO.ZS?locations=JP-IT-PT-DE-FI&most_recent_value_desc=false. Accessed 10 Mar 2021"}],"container-title":["European Journal of Medical Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40001-025-03297-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40001-025-03297-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40001-025-03297-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T13:25:06Z","timestamp":1761744306000},"score":1,"resource":{"primary":{"URL":"https:\/\/eurjmedres.biomedcentral.com\/articles\/10.1186\/s40001-025-03297-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,29]]},"references-count":33,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["3297"],"URL":"https:\/\/doi.org\/10.1186\/s40001-025-03297-6","relation":{},"ISSN":["2047-783X"],"issn-type":[{"value":"2047-783X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,29]]},"assertion":[{"value":"6 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Written informed consent was obtained from all patients at enrollment into the ZGDH3 trial. No additional consent was required for this post hoc analysis, as all data were de-identified and analyzed in accordance with the Declaration of Helsinki.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1040"}}